A Phase IB, Proof of Mechanism, Open-Label Study of RO7070179, A Hypoxia-inducible Factor 1A(HIH1A) mRNA Antagonist In Adult Subjects with Hepatocellular Carcinoma (HCC)
A study for patients with liver cancer using study drug RO7070179
Sponsor: Hoffmann-La Roche
Enrolling: Male and Female Patients
IRB Number: AAAQ4550
U.S. Govt. ID: NCT02564614
Contact: Gulam Manji: 212-305-7115 / gam2140@cumc.columbia.edu
Additional Study Information: The purpose of this study is to assess the safety, tolerability, and effectiveness of RO7070179 given to patients with Hepatocellular Carcinoma (HCC), a primary type of liver cancer, with normal to moderately impaired liver function. RO7070179 is given intravenously to study its effects in the treatment of liver cancer. RO7070179 is an investigational anti-cancer agent and acts by inhibiting the growth of the tumor. It is designed to lower the amount of a protein called hypoxia-indicible factor-1 alpha (HIF1A). HIF1A helps cancer cells survive when hypoxia occurs (low oxygen). RO7070179 lowers the amount of HIF1A by binding and destroying the message that tells the cancer cells to make HIF1A. However, it is not known if RO7070179 will lower the amount of HIF1A in HCC and if this will slow the growth of HCC. The study plans to find out whether RO7070179 affects the amount of HIF1A RNA present and whether HIF1A protein is reduced in the tumors of patients with HCC. The study will also find out if the drug is safe in patients with HCC and whether the tumor of patients with HCC are affected in an open-label study design.
This study is closed
Gulam Manji, MD, PhD
Do You Qualify?
Have you been diagnosed with liver cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Gulam Manji